SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01657786

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting

Postoperative nausea and vomiting (PONV) is a common and distressing complication in patients undergoing general anesthesia. However, although 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists have significantly reduced PONV, it is reported that over 35% of patients treated with ondansetron experience PONV. Though the cause of failure in ondansetron treatment is not clear, the investigators assumed that polymorphism in the 5-HT3 receptor gene would contribute to such inter-individual variation. In this study, the investigators examine whether the polymorphisms of 5-HT3 receptor gene affect the efficacy of ondansetron to prevent PONV in patients undergoing general anesthesia for laparoscopic surgery.

NCT01657786 Post Operative Nausea and Vomiting
MeSH:Nausea Vomiting Postoperative Nausea and Vomiting
HPO:Nausea Vomiting

1 Interventions

Name: administration of ondanstron and screening of genomic DNA

Description: Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
Type: Dietary Supplement
Group Labels: 1

Ondansetron administration group


Primary Outcomes

Description: The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).

Measure: The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG)

Time: at first 2 h and 2-24 h after surgery.

Allocation: N/A

Single Group Assignment


There are 2 SNPs

SNPs


1 S253N

The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG). --- S253N ---

The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).. Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Post Operative Nausea and Vomiting Nausea Vomiting Postoperative Nausea and Vomiting null --- S253N ---


2 Y129S

The relationship between the incidence of PONV after ondansetron administration and genotypes in 5-HT3 receptor gene polymorphisms ((5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG). --- S253N --- --- Y129S ---

The incidence of PONV after ondansetron administration is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).. Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Inclusion Criteria: - Adult patients (20-90 years of age) scheduled for undergoing laparoscopic surgery undergoing general anesthesia Exclusion Criteria: - Patients with previous history of drug allergy, - administration of antiemetic drugs within 24 hours, - nausea/vomiting within 24 hours and liver or kidney disease Post Operative Nausea and Vomiting Nausea Vomiting Postoperative Nausea and Vomiting null --- S253N --- --- Y129S ---



HPO Nodes


HPO:
HP:0002013: Vomiting
Genes 263
PYCR2 NDUFA6 ACAT1 PMM2 GALT COQ2 ST3GAL5 KCNJ11 NDUFAF4 ND5 HLCS TRNS2 ND2 MLYCD MC2R POLG IVD BCKDHB ABCC8 ACADVL HFE POLG ETFDH COX3 PIGY PPM1D MRAP SERPING1 FOXP3 TRNS1 UCP2 GK CPOX C11ORF95 ND4 IRAK1 PDCD10 SHANK3 RELA GCDH TRNF AIP CPS1 SCNN1G CDH23 DGAT1 SLC12A1 CFI ALDH18A1 NDUFV1 TRMU NDUFS4 ALG11 TRNK CPT2 NDUFS3 MCCC1 ACAD8 ACP2 TRNW ALG3 CYTB NFIX SLC6A8 ELP1 NDUFS1 KMT2E RANBP2 OXCT1 PPOX MTHFD1 SERPING1 ABCC8 TYMP NDUFS6 ACADL NDUFAF3 RARS1 SCNN1A BCKDHA SERPING1 NDUFV1 ACADM NEUROG3 KRIT1 FBP1 ND3 HMGCL ALG8 TMEM126B CTNS HELLPAR CYP11A1 ND1 DHCR7 ACTG2 PCCB HSD3B2 TP53 CD46 SCNN1B DBH DGUOK BRAF EGFR ND3 TIMMDC1 HPRT1 STAR ALDOB NDUFAF5 GALC POLG NDUFS2 ACSF3 ALAD ACSF3 GALE ST3GAL5 NAGS MMAA INHBA COX2 NDUFS8 FLNA ND1 ADNP TRNK C1R TRNL1 SLC25A15 SSR4 MET SAR1B KCNJ11 SLC12A3 CD55 SLC7A7 CYTB TRNV PDSS2 NDUFB10 SAA1 ACAT1 NEUROG3 ND1 NAXD GLA ATRX LPL STK11 RET ATP6V0A4 SAR1B TRNL1 ND6 NNT COA8 CYP24A1 ACY1 ETFA ND2 CACNA1A EDNRA KCNJ1 MVK MTRR SLC1A3 NDUFS4 ND5 NDUFB11 CLMP STAT4 MVK DLD SLC22A5 HMGCL TCN2 CYP11B1 ARG1 TNFRSF1A SUGCT TYMP SLC25A13 PCCA D2HGDH LIPA SLC7A7 OTC MPI SMPD1 HMBS F12 NBAS TXNRD2 AVPR2 ATP6 ACADVL ZEB2 OPLAH TRNQ ASL ALPL PNPLA8 MMUT C1QA NUBPL MCCC2 PMM2 AVP COX1 CDH23 ALDOB NDUFA11 CYP11B2 HIBCH RRM2B AIMP1 NDUFS1 NDUFAF2 SLC25A15 NDUFV2 MEN1 SLC22A5 NR3C2 MRPS7 NDUFB9 HADH TNF BOLA3 FOXRED1 SPP1 NDUFS7 TRNV CTNNB1 AQP2 HNF1A NAGS FARSB GHSR ESR1 APC HNF4A NDUFAF1 CCM2 MMAB ALG11 ND6 MPV17 NDUFB3 ACADM CFH DBT PHGDH SYT1 CYP11A1 BTD ASS1 NDUFA1 HMGCS2 ETFB TRNC TRNW
Protein Mutations 3
S253N V158M Y129S
SNP 1
rs4680